ArticleJAMA2024
Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023.
Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Feasibility and Acceptability of a mHealth Patient Navigation Intervention to Increase Pre-Exposure Prophylaxis Uptake in Racially and Ethnically Diverse Sexual and Gender Minority Youth in Los Angeles (PrEPresent): Pilot Randomized Controlled Trial.JMIR formative research · 2025Trial
- Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database.Clinical drug investigation · 2026Article
- 'Educating, demystifying, destigmatising': Black women's perspectives on effective PrEP messaging in the USA.Culture, health & sexuality · 2026Article
- Barriers and Facilitators to Equitable Implementation of Long-Acting Injectable PrEP for Racial, Gender and Sexual Minority Populations in NYC: The EquiPrEP Study.AIDS and behavior · 2026Article
- Evolving drivers of preexposure prophylaxis discontinuation among US MSM, 2018-2024.AIDS (London, England) · 2026Article
- Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- What Tools Do We Have to End the US HIV Epidemic? A Review of Structural, Biomedical and Implementation Interventions and Their Potential Population Impact.Journal of the International AIDS Society · 2026Review
- Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.JAMA network open · 2026Article
- HIV Preexposure Prophylaxis Prescriptions Among Black and Hispanic or Latino Populations.JAMA network open · 2026Article
- Perceptions of donor screening-Do I always need to tell the truth?Transfusion medicine (Oxford, England) · 2026Article
- Identification of Provider Barriers and Facilitators to Integration of Pre-Exposure Prophylaxis into Postpartum Care.AIDS patient care and STDs · 2026Article
- Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- HIV-1 Prevalence and Oral Pre-Exposure Prophylaxis Effectiveness and Prevalence of Use Among Key Populations in High-Income Economies (2017-2023): A Systematic Review and Meta-Analysis of Real-World Studies.Open forum infectious diseases · 2026Review
- National Trends in HIV Pre-Exposure Prophylaxis Dispensing to Young Adults, 2016-2023.Journal of general internal medicine · 2026Article
- Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.Journal of general internal medicine · 2026Article
- "The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP.AIDS and behavior · 2025Article
- Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.Lancet regional health. Americas · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.